search

Active clinical trials for "Motor Neuron Disease"

Results 401-410 of 760

Neuromuscular Magnetic Stimulation in ALS Patients

Amyotrophic Lateral Sclerosis

Aim of the study is to verify whether neuromuscular magnetic stimulation can improve muscle function in spinal-onset Amyotrophic Lateral Sclerosis (ALS) patients.

Completed7 enrollment criteria

A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral SclerosisMotor Neuron Disease

This is a phase II study to determine the safety and tolerability of ILB , a type of low molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)

Completed16 enrollment criteria

Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

Amyotrophic Lateral SclerosisALS

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).

Completed26 enrollment criteria

Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS)...

Amyotrophic Lateral Sclerosis

The LIPCAL-ALS study (NCT02306590) has provided preliminary evidence that a high-caloric nutrition might prolong survival in fast-progressing ALS patients. Since increasing the amount of calories of the intervention might possibly increase the beneficial effect, the investigators seek to investigate whether an ultra-high caloric diet (UHCD), featuring the double amount of calories compared to LIPCAL-ALS, will be well tolerated by ALS patients and may serve as an intervention for a potential LIPCALII study. For this purpose, the investigators will compare two different UHCDs (one fat-rich and one carbohydrate-rich) with regard to safety and tolerability over a time frame of 4 weeks. A third group will receive the original diet from LIPCAL, and a fourth group will receive no intervention (control group).

Completed8 enrollment criteria

A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS...

Amyotrophic Lateral SclerosisALS

ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support. In addition, time from diagnosis to death averages 3-5 years. New Biotic, LLC has submitted an Orphan Drug Designation Application for an investigational probiotic and have indicated the need for more study of this orphaned drug in ALS patients.

Completed8 enrollment criteria

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Motor Neuron DiseaseAmyotrophic Lateral Sclerosis

Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. Safety, tolerability, immunogenicity, and PK/PD will be measured. To evaluate feasibility of the endpoints, additional endpoints of ALSFRS-R, respiratory function tests, disease biomarkers and patient-reported outcomes will be measured.

Completed44 enrollment criteria

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis...

Amyotrophic Lateral Sclerosis

The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.

Completed16 enrollment criteria

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Amyotrophic Lateral Sclerosis

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.

Completed5 enrollment criteria

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Amyotrophic Lateral Sclerosis

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in participants with ALS.

Completed4 enrollment criteria

Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

To evaluate the safety and effectiveness of intravenous infusion of plasma from healthy young people for the treatment of amyotrophic lateral sclerosis.

Completed21 enrollment criteria
1...404142...76

Need Help? Contact our team!


We'll reach out to this number within 24 hrs